DAVID BROWNFORD WEBER
Pilots at Woodranch Cir, Danville, CA
License number
California A4140519
Issued Date
Nov 2016
Expiration Date
May 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
48 Woodranch Cir, Danville, CA 94506
Professional information
Drug Delivery Systems For Treatment Of Diseases Or Conditions
US Patent:
2006025, Nov 16, 2006
Filed:
Mar 21, 2006
Appl. No.:
11/386290
Inventors:
Sreenivasu Mudumba - Union City CA, US
Philippe Jm Dor - Cupertino CA, US
Thierry Nivaggioli - Atherton CA, US
David Weber - Danville CA, US
Sidiq Farooq - Newark CA, US
Philippe Jm Dor - Cupertino CA, US
Thierry Nivaggioli - Atherton CA, US
David Weber - Danville CA, US
Sidiq Farooq - Newark CA, US
International Classification:
A61K 31/4745, A61F 2/02
US Classification:
424427000, 514291000
Abstract:
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of therapeutic agents to such tissues. A solid drug delivery system may be placed in a subject, including but not limited to placement between the sclera and the conjunctiva or transscleral placement. Described methods may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, age-related macular degeneration, or wet age-related macular degeneration in a subject. The solid drug delivery devices may comprise rapamycin or other therapeutic agents. Also described are methods of treating ocular diseases or disorders by administering an antiproliferative agent, including but not limited to rapamycin, proximal to an ocular device.
Liquid Formulations For Treatment Of Diseases Or Conditions
US Patent:
2006025, Nov 16, 2006
Filed:
Feb 9, 2006
Appl. No.:
11/351761
Inventors:
Sreenivasu Mudumba - Union City CA, US
Philippe Dor - Cupertino CA, US
Thierry Nivaggioli - Atherton CA, US
David Weber - Danville CA, US
Sidiq Farooq - Newark CA, US
Philippe Dor - Cupertino CA, US
Thierry Nivaggioli - Atherton CA, US
David Weber - Danville CA, US
Sidiq Farooq - Newark CA, US
International Classification:
A61K 31/4745
US Classification:
514291000
Abstract:
Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.
Ocular Implant Made By A Double Extrusion Process
US Patent:
2013023, Sep 5, 2013
Filed:
Mar 12, 2013
Appl. No.:
13/797230
Inventors:
Rahul Bhagat - Irvine CA, US
Wendy M. Blanda - Tustin CA, US
Thierry Nivaggioli - Atherton CA, US
Lin Peng - South San Francisco CA, US
David Chou - Palo Alto CA, US
David A. Weber - Danville CA, US
Wendy M. Blanda - Tustin CA, US
Thierry Nivaggioli - Atherton CA, US
Lin Peng - South San Francisco CA, US
David Chou - Palo Alto CA, US
David A. Weber - Danville CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 9/00, A61K 31/573
US Classification:
514180, 264119
Abstract:
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Methods And Apparatus For Delivery Of Ocular Implants
US Patent:
6899717, May 31, 2005
Filed:
Sep 18, 2002
Appl. No.:
10/246884
Inventors:
David Weber - Danville CA, US
Ingrid Kane - Los Altos CA, US
Mike Rehal - Boulder Creek CA, US
Kenny Aptekarev - Santa Cruz CA, US
Ingrid Kane - Los Altos CA, US
Mike Rehal - Boulder Creek CA, US
Kenny Aptekarev - Santa Cruz CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61F009/00
US Classification:
606107
Abstract:
An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
Methods For Treating Retinopathy With Extended Therapeutic Effect
US Patent:
2006023, Oct 19, 2006
Filed:
Dec 2, 2005
Appl. No.:
11/292544
Inventors:
Scott Whitcup - Laguna Hills CA, US
David Weber - Danville CA, US
David Weber - Danville CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 31/573, A61F 2/00
US Classification:
424427000, 514179000
Abstract:
Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
Extended Therapeutic Effect Ocular Implant Treatments
US Patent:
2008024, Oct 2, 2008
Filed:
Mar 25, 2008
Appl. No.:
12/055224
Inventors:
Scott M. WHITCUP - Laguna Hills CA, US
David A. Weber - Danville CA, US
David A. Weber - Danville CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61F 2/00, A61K 31/56
US Classification:
424428, 424427, 514180
Abstract:
Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
Biodegradable Ocular Implant
US Patent:
2004013, Jul 15, 2004
Filed:
Jan 9, 2003
Appl. No.:
10/340237
Inventors:
Thierry Nivaggioli - San Francisco CA, US
Lin Peng - San Jose CA, US
David Chou - Palo Alto CA, US
David Weber - Danville CA, US
Lin Peng - San Jose CA, US
David Chou - Palo Alto CA, US
David Weber - Danville CA, US
International Classification:
A61K009/22
US Classification:
424/468000, 514/179000
Abstract:
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Methods And Apparatus For Delivery Of Ocular Implants
US Patent:
7090681, Aug 15, 2006
Filed:
Sep 18, 2003
Appl. No.:
10/666872
Inventors:
David A. Weber - Danville CA, US
Ingrid Kane - Los Altos CA, US
Mike Rehal - Boulder Creek CA, US
Kenny Aptekarev - Santa Cruz CA, US
Jeffrey Etter - Hayward CA, US
Ingrid Kane - Los Altos CA, US
Mike Rehal - Boulder Creek CA, US
Kenny Aptekarev - Santa Cruz CA, US
Jeffrey Etter - Hayward CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61F 9/00
US Classification:
606107, 623 611
Abstract:
An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
Extended Therapeutic Effect Ocular Implant Treatments
US Patent:
2008024, Oct 2, 2008
Filed:
Mar 25, 2008
Appl. No.:
12/055228
Inventors:
Scott M. WHITCUP - Laguna Hills CA, US
David A. Weber - Danville CA, US
David A. Weber - Danville CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61F 2/00, A61K 31/56
US Classification:
424428, 424427, 514180
Abstract:
Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
Ocular Implant Made By A Double Extrusion Process
US Patent:
2005004, Mar 3, 2005
Filed:
Aug 13, 2004
Appl. No.:
10/918597
Inventors:
Rahul Bhagat - Irvine CA, US
Thierry Nivaggioli - Los Altos CA, US
Lin Peng - South San Francisco CA, US
David Chou - Palo Alto CA, US
David Weber - Danville CA, US
Thierry Nivaggioli - Los Altos CA, US
Lin Peng - South San Francisco CA, US
David Chou - Palo Alto CA, US
David Weber - Danville CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K031/56, A61F002/00
US Classification:
424428000, 514171000
Abstract:
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.